Hematologic Malignancy
T-Cell and NK-Cell Neoplasm
CI-CAN-00001561Explore in graph →
HematologicNon-malignant268 active trials13 approved drugs18 evidence items
- NCIt
- C27908
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001561Explore in graph →
Clinical trials
1,103 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07725705 | SHR2554 Plus Liposomal Mitoxantrone as First-line Treatment for Peripheral T-cell Lymphoma (PTCL) | not yet recruiting | Phase 1 / Phase 2 | 44 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Jul 24, 2026 | clinicaltrials |
| NCT07717580 | Efficacy and Safety of Brentuximab Vedotin Combined With Lisaftoclax in CD30+ Cutaneous T-cell Lymphoma (CTCL)(BV-LISA-CTCL) | not yet recruiting | Phase 2 | 46 | Peking University First HospitalOTHER |
| 1 |
| Jul 23, 2026 |
| clinicaltrials |
| NCT04703192 | Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01) | active not recruiting | Phase 2 | 155 | Daiichi SankyoINDUSTRY | 12 | Jul 20, 2026 | clinicaltrials |
| NCT06810778 | Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) | recruiting | Phase 1 / Phase 2 | 12 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT01352520 | SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP) | active not recruiting | Phase 2 | 79 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07706959 | New Genotype-guided Treatment in Newly Diagnosed PTCL(G08) | not yet recruiting | Phase 1 / Phase 2 | 108 | Ruijin HospitalOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT00501826 | Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | recruiting | Phase 2 | 160 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT06580002 | Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial | recruiting | Phase 2 | 75 | University of California, IrvineOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT06698822 | A Phase 2 Trial to Assess Safety and Efficacy of Tofacitinib 2% Cream in the Treatment of Cutaneous T-cell Lymphoma (CTCL), Stages IA, IB, and IIA | recruiting | Phase 2 | 20 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT05805605 | Allo HSCT Using RIC and PTCy for Hematological Diseases | recruiting | Phase 2 | 56 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07682792 | Golidocitinib in Patients With Mycosis Fungoides/Sézary Syndrome and T-Cell Large Granular Lymphocytic Leukemia(GEMSTONE) | not yet recruiting | Phase 2 | 24 | Washington University School of MedicineOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT04256018 | Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome | recruiting | Phase 2 | 30 | Stanford UniversityOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07678307 | A Multicenter, Open-label, Non-randomized, Single-arm Phase 1/2 Study of Autologous Nano CD5-CAR T Cells for the Treatment of Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma | not yet recruiting | Phase 1 / Phase 2 | 18 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Jul 1, 2026 | clinicaltrials |
| NCT07676175 | A Study of BEBT-908 in Combination With Chemotherapy in Patients With Previously Untreated Peripheral T-Cell Lymphoma (PTCL) | not yet recruiting | Phase 2 | 120 | BeBetter Med IncINDUSTRY | 1 | Jun 30, 2026 | clinicaltrials |
| NCT01657331 | Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL)(SGN+Benda) | completed | Phase 1 / Phase 2 | 65 | Columbia UniversityOTHER | 2 | Jun 24, 2026 | clinicaltrials |
| NCT04068597 | Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies | recruiting | Phase 1 / Phase 2 | 250 | CellCentric Ltd.INDUSTRY | 5 | Jun 24, 2026 | clinicaltrials |
| NCT07658924 | Efficacy and Safety of Benvitimod Cream in Cutaneous T-Cell Lymphoma(BEST-CTCL) | not yet recruiting | Phase 2 | 35 | Peking University First HospitalOTHER | 0 | Jun 22, 2026 | clinicaltrials |
| NCT07502768 | Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma(EpiRev-NKT) | recruiting | Phase 1 / Phase 2 | 107 | Rong TaoOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT05475925 | A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas | recruiting | Phase 1 / Phase 2 | 200 | Dren BioINDUSTRY | 9 | Jun 17, 2026 | clinicaltrials |
| NCT05463263 | A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas | recruiting | Phase 1 / Phase 2 | 180 | Step Pharma, SASINDUSTRY | 3 | Jun 16, 2026 | clinicaltrials |
| NCT02232516 | Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma | completed | Phase 2 | 30 | Northwestern UniversityOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT04960618 | Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome | active not recruiting | Phase 2 | 14 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05313243 | Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma | recruiting | Phase 2 | 32 | Yale UniversityOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT03505554 | A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma(CRU3) | completed | Phase 2 | 9 | University of Milano BicoccaOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07636564 | Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment | not yet recruiting | Phase 2 | 90 | SWOG Cancer Research NetworkNETWORK | 0 | Jun 9, 2026 | clinicaltrials |
| NCT04984837 | Study of Lacutamab in Peripheral T-cell Lymphoma | active not recruiting | Phase 2 | 49 | The Lymphoma Academic Research OrganisationOTHER | 4 | Jun 4, 2026 | clinicaltrials |
| NCT07555431 | Dolutegravir Versus Dolutegravir in Combination With Tenofovir for the Treatment of HTLV-1 Infection(DOT-H) | recruiting | Phase 2 | 146 | Carlos BritesOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT04195633 | Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies | recruiting | Phase 2 | 60 | Fred Hutchinson Cancer CenterOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT03598998 | Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas | active not recruiting | Phase 1 / Phase 2 | 13 | City of Hope Medical CenterOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT07013565 | Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL(ACCELERATE) | recruiting | Phase 2 | 20 | New York Medical CollegeOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT02362997 | Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL | completed | Phase 2 | 82 | Dana-Farber Cancer InstituteOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT02797470 | Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant | active not recruiting | Phase 1 / Phase 2 | 11 | AIDS Malignancy ConsortiumNETWORK | 1 | May 18, 2026 | clinicaltrials |
| NCT02943642 | Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein in Subjects With Mycosis Fungoides(Resimmune®) | withdrawn | Phase 2 | 0 | Virogen Biotechnology Inc.INDUSTRY | 0 | May 18, 2026 | clinicaltrials |
| NCT05976997 | Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL) | recruiting | Phase 2 | 36 | Liling ZhangOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT07585734 | Clinical Trial of CD38 Monoclonal Antibody Combined With Chemotherapy for T-Cell Acute Lymphoblastic Leukemia | withdrawn | Phase 1 / Phase 2 | 0 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | May 14, 2026 | clinicaltrials |
| NCT03808610 | Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia | terminated | Phase 1 / Phase 2 | 53 | M.D. Anderson Cancer CenterOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT07225985 | Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma | recruiting | Phase 1 / Phase 2 | 50 | Fred Hutchinson Cancer CenterOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT03927105 | Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma | completed | Phase 2 | 4 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT06874946 | Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL(Phase I/II) | recruiting | Phase 1 / Phase 2 | 30 | Peking University People's HospitalOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT04331119 | Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas | terminated | Phase 2 | 17 | Washington University School of MedicineOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT05532722 | ABC008 in Subjects With T-cell Large Granular Lymphocytic Leukemia (T-LGLL) | completed | Phase 1 / Phase 2 | 21 | Abcuro, Inc.INDUSTRY | 1 | May 6, 2026 | clinicaltrials |
| NCT05956041 | Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas | recruiting | Phase 2 | 23 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT03035331 | Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 11 | Mayo ClinicOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT03902184 | IPH4102/Lacutamab Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma(TELLOMAK) | completed | Phase 2 | 170 | Innate PharmaINDUSTRY | 8 | Apr 29, 2026 | clinicaltrials |
| NCT07075328 | A Phase I/II Study of OJP-001 in Patients With Adult T-cell Leukemia/Lymphoma | recruiting | Phase 1 / Phase 2 | 49 | Otsuka Medical Devices Co., Ltd. JapanINDUSTRY | 1 | Apr 29, 2026 | clinicaltrials |
| NCT07554482 | Selinexor Combined With Reduced-Dose Radiotherapy For Early-Stage Extranodal NK/T-Cell Lymphoma | not yet recruiting | Phase 2 | 34 | Beijing Tongren HospitalOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT05680558 | Photopheresis in Early-stage Mycosis Fungoides | recruiting | Phase 2 | 74 | Columbia UniversityOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT07496229 | Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3) | recruiting | Phase 1 / Phase 2 | 165 | Dizal PharmaceuticalsINDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT07535710 | Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma | not yet recruiting | Phase 1 / Phase 2 | 37 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT07535762 | Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Untreated Peripheral T-Cell Lymphoma | not yet recruiting | Phase 2 | 36 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Apr 17, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Jul 24, 2026source: clinicaltrials